IRON DISC MEDICINE INC

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at three upcoming investor conferences:

  • TD Cowen 45th Annual Health Care Conference (Boston, MA): Corporate presentation on Wednesday, March 5th at 9:10 a.m. ET.

  • Leerink Global Healthcare Conference (Miami, FL): Fireside chat on Monday, March 10th at 2:20 p.m. ET.
  • Barclays 27th Annual Global Healthcare Conference (Miami, FL): Fireside chat on Thursday, March 13th at 9:30 a.m. ET.

Disc management will be participating in investor meetings during each of the above conferences, as well as the Jefferies Biotech on the Beach Summit in Miami, FL. The Jefferies meetings take place on Tuesday, March 11th.

Live webcasts of the corporate presentation and fireside chats will be available through the investor relations section of the Company's website at and an archived replay will be available after the event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit .

Media Contact

Peg Rusconi

Deerfield Group

Investor Relations Contact

Christina Tartaglia

Precision AQ



EN
26/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DISC MEDICINE INC

 PRESS RELEASE

Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of My...

Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF) WATERTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will host a virtual KOL investor event on Friday, May 9 at 1:00 PM ET / 10:00 AM PT to provide an overview of anemia of myelofibrosis (MF) and discuss the evolving treatment landscape for this disease. The event will al...

 PRESS RELEASE

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Resu...

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketing confirmatory trial by mid-2025Positive update from Phase 1b trial of DISC-0974 in patients with anemia of myelofibrosis (MF) presented at ASH 2024; initial data from ongoing Phase 2 expected in H2 2025Positive data from initial cohorts of ongoing Phase 1b study of DISC-0974 in patients with anemia of non-dialysis-dependen...

 PRESS RELEASE

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at three upcoming investor conferences: TD Cowen 45th Annual Health Care Conference (Boston, MA): Corporate presentation on Wednesday, March 5th at 9:10 a.m. ET.Leerink Global Healthcare Conference (Miami, FL):...

 PRESS RELEASE

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offer...

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants WATERTOWN, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of its upsized underwritten offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of i...

 PRESS RELEASE

Disc Medicine Announces Proposed Public Offering of Common Stock and P...

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants WATERTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it has commenced an underwritten offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch